Results 131 to 140 of about 15,584 (193)

The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review

ESC Heart Failure, Volume 12, Issue 2, Page 980-997, April 2025.
Abstract Heart failure (HF) creates a considerable clinical, humanistic and economic burden on patients and caregivers as well as on healthcare systems. To attenuate the significant burden of HF, there is a need for enhanced management of patients with HF.
Javed Butler, Malcolm Brown, Philippe Prokocimer, Ashley C. Humphries, Sophie Pope, Olivia Wright, Jun Su, Osama Elnawasany, Bogdan Muresan   +8 more
wiley   +1 more source

D145. Advances in Pre-treatments of the Ex-vivo Vascularized Composite Allograft: A Systematic Review

Plastic and Reconstructive Surgery, Global Open
Caroline E. Baker, BSE, Thor S. Stead, ScB, David L. Tran, MD, Alay R. Shah, MD, Hilliard T. Brydges, BS, Matteo Laspro, BA, Bruce E. Gelb, MD, Eduardo D. Rodriguez, MD, DDS, Piul S. Rabbani, PhD   +8 more
doaj   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

The Crowd: Zooming in on Social Behaviour

European Journal of Social Psychology, EarlyView.
ABSTRACT The direct observation of social behaviour has almost completely vanished from socialpsychological research, in favour of studies of attitudes, identities and cognitions. Using crowd psychology as an illustration, this article argues for a renewed focus on observational research enabled by recent technological advances, including high ...
Tom Postmes, Armin Seyfried, Anna Sieben
wiley   +1 more source

Long‐term prediction of epilepsy following traumatic brain injury among veterans using routine clinical data

Epilepsia, EarlyView.
Abstract Objective Despite elevated risk for epilepsy following traumatic brain injury (TBI), there are limited tools to assess epilepsy risk following TBI using routine clinical data. The objective of this study was to develop and validate a machine learning approach to predict the onset of posttraumatic epilepsy (PTE) over varying time horizons ...
Mustafa Ozmen, Shashank Vadlamani, James J. Gugger, Megan Amuan, Ramon Diaz‐Arrastia, Mary Jo Pugh, Eamonn Kennedy   +6 more
wiley   +1 more source

Selective γ8 transmembrane α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor regulatory protein negative allosteric modulators: Efficacy in preclinical antiseizure models

Epilepsia, EarlyView.
Abstract Objective RAP‐219, a potent selective negative allosteric modulator (NAM) of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor (AMPAR) associated with γ8 transmembrane AMPAR regulatory protein (TARPγ8), is in phase 3 development for refractory focal epilepsy. This study was undertaken to assess efficacy and motor function following
Jose A. Matta, Brock T. Shireman, Laurie P. Volak, Michael P. Maher, Michael K. Ameriks, David Bredt   +5 more
wiley   +1 more source